In a study of African-American men, researchers say they’ve linked two genetic variants to severity of lower urinary tract symptoms related to BPH, giving scientists insight into the higher risk facing African-Americans.
Most urologists agree that surgical removal of the enlarged portion of the prostate is the most effective and durable way to manage lower urinary tract symptoms in men secondary to BPH. Where it gets interesting is deriving urologic consensus on the best way to achieve that goal.
A new study has found that testosterone replacement doesn’t worsen lower urinary tract symptoms related to an enlarged prostate. In fact, many men saw their symptoms improve, apparently with little effect on their prostate gland.
In the treatment of BPH, while both bipolar-transurethral resection of the prostate (B-TURP) and monopolar-TURP (M-TURP) have similar clinical efficacy, B-TURP is associated with fewer adverse events, according to a recent systematic review of the two modalities.
As follow-up lengthens in a prospective, randomized, controlled trial, men who underwent bipolar plasma vaporization of the prostate for BPH using the “button” vapo-resection electrode continue to demonstrate significantly better symptom scores and voiding characteristics compared to their counterparts treated by bipolar transurethral resection in saline or monopolar transurethral resection of the prostate.
The new-generation GreenLight XPS-180W laser system (American Medical Systems, Minnetonka, MN) achieved an improved rate of tissue vaporization and overall efficacy in patients with BPH compared to an earlier generation laser, according to results of a recent multicenter study.